| Bioactivity | OHM1 is an analog of HIF1α CTAD that inhibits its binding with p300/CBP. OHM1 targets CH1 domain with an affinity of 0.53 μM[1]. |
| Invitro | OHM1 (1-20 μM; 24 h) 导致 HIF 启动子活性呈剂量依赖性降低，并在 20 μM 使 MDA-MB-231 细胞在低氧条件下的 HIF1α 转录活性降低至常氧条件下[1].OHM1 下调缺氧诱导基因表达[1]。OHM1 (10 μM) 下调了 A549 非小细胞肺癌细胞系中与血管生成、凋亡、细胞增殖和侵袭相关的多个基因，以及几种癌症特异性标记物[1]。 RT-PCR[1] Cell Line: |
| In Vivo | OHM1 (15 mg/kg; i.p.; every other day for 15 injections) 降低小鼠 MDA-MB-231 肿瘤体积[1]。 Animal Model: |
| Name | OHM1 |
| CAS | 1450995-09-1 |
| Formula | C24H42N6O5 |
| Molar Mass | 494.63 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Lao BB, et al. In vivo modulation of hypoxia-inducible signaling by topographical helix mimetics. Proc Natl Acad Sci U S A. 2014 May 27;111(21):7531-6. |